Targeting undruggable proteins promises new approach for treating neurodegenerative diseases phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.
A groundbreaking study introduces a new method of targeting 'undruggable' proteins to fight neurodegenerative diseases by enhancing cellular antioxidant defenses, offering new hope for treatment advancements. Researchers led by Northwestern University and the University of Wisconsin-Madison have
Researchers led by Northwestern University and the University of Wisconsin-Madison have introduced a pioneering approach aimed at combating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis (ALS).
<p>In a new study, researchers discovered a new way to enhance the body’s antioxidant response, which is crucial for cellular protection against the oxidative stress implicated in many neurodegenerative diseases. The pioneering approach might inform treatments for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis (ALS).</p>
Grove Biopharma Launches with a Novel Biotherapeutic Modality Platform; Portal Innovations Leads Oversubscribed Seed-Stage Investment
Share Article
Leverages Biomaterial Discoveries and Insights from Award Winning Scientist Nathan Gianneschi, Ph.D. With an Initial Focus on Neurodegenerative Diseases
Professor Gianneschi’s protein-like polymer (PLP) platform is a revolutionary innovation at the interface between materials engineering, biology, chemistry, and data science with the potential to address important biological disease targets including those classically considered to be undruggable. CHICAGO (PRWEB) May 10, 2021 Portal Innovations, a premier life sciences venture development engine, today announced that Grove Biopharma has successfully closed an oversubscribed $4 million seed round and will become a portfolio member at its Fulton Labs location. Other noteworthy participants in the financing include Jo